Similar articles for PMID: 27190603

Year	Number of Results
2005	1
2007	3
2009	2
2010	2
2011	2
2012	8
2013	6
2014	4
2015	15
2016	21
2017	16
2018	9
2019	1
2024	0

1

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X. Hennessy EJ, et al. ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. doi: 10.1021/acsmedchemlett.6b00058. eCollection 2016 May 12. ACS Med Chem Lett. 2016. PMID: 27190603 Free PMC article.

2

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ. Jia Y, et al. Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25. Nature. 2016. PMID: 27251290 Free PMC article.

3

JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.

Nishiya N, Sakamoto Y, Oku Y, Nonaka T, Uehara Y. Nishiya N, et al. World J Biol Chem. 2015 Nov 26;6(4):409-18. doi: 10.4331/wjbc.v6.i4.409. World J Biol Chem. 2015. PMID: 26629323 Free PMC article.

4

Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

Hao Y, Wang X, Zhang T, Sun D, Tong Y, Xu Y, Chen H, Tong L, Zhu L, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Hao Y, et al. J Med Chem. 2016 Aug 11;59(15):7111-24. doi: 10.1021/acs.jmedchem.6b00403. Epub 2016 Jul 21. J Med Chem. 2016. PMID: 27396610

5

Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.

Song X, Liu X, Ding X. Song X, et al. J Mol Recognit. 2017 Apr;30(4). doi: 10.1002/jmr.2590. Epub 2016 Nov 28. J Mol Recognit. 2017. PMID: 27891677

6

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Yamada T, et al. Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15. Clin Cancer Res. 2010. PMID: 20008840

7

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St Jean DJ Jr, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Wurz RP, et al. ACS Med Chem Lett. 2015 Jul 27;6(9):987-92. doi: 10.1021/acsmedchemlett.5b00193. eCollection 2015 Sep 10. ACS Med Chem Lett. 2015. PMID: 26396685 Free PMC article.

8

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S. Otani H, et al. PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015. PLoS One. 2015. PMID: 26090892 Free PMC article.

9

Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.

Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Li H. Zhou W, et al. J Med Chem. 2013 Oct 24;56(20):7821-37. doi: 10.1021/jm401045n. Epub 2013 Oct 9. J Med Chem. 2013. PMID: 24053674

10

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY. Lelais G, et al. J Med Chem. 2016 Jul 28;59(14):6671-89. doi: 10.1021/acs.jmedchem.5b01985. Epub 2016 Jul 19. J Med Chem. 2016. PMID: 27433829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

76 results

Results by year